Key result
Metabolic syndrome was associated with higher in-hospital mortality following mitral valve surgery (6.5% vs. 2%, p<0.001), but not after surgical or transcatheter aortic valve replacement.
Why the study?
The effect of metabolic syndrome on postoperative complications following isolated heart valve intervention remains controversial.
Does metabolic syndrome increase in-hospital mortality and postoperative length of stay in patients undergoing heart valve intervention?
Cohort (n=17,283)
Yes
Does metabolic syndrome increase in-hospital mortality and postoperative length of stay in patients undergoing heart valve intervention?
Answers are grounded in this paper and cite their sources.
Metabolic syndrome is associated with higher in-hospital mortality and complications following mitral valve surgery, but does not significantly impact mortality in surgical or transcatheter aortic valve replacement.
BACKGROUND: The effect of metabolic syndrome (MetS), defined as insulin resistance along with two or more of: obesity, atherogenic dyslipidaemia and elevated blood pressure, on postoperative complications after isolated heart valve intervention remains controversial. We hypothesized that MetS may negatively influence the postoperative course in these patients. METHODS: tricuspid repair/replacement (mitral valve surgery [MVS]) or surgical aortic valve replacement (SAVR), or transcatheter aortic valve replacement (TAVR) were included. MetS was defined according to the World Health Organization criteria. Primary outcome was in-hospital mortality and overall postoperative length of stay (LOS). Relevant postoperative complications were also recorded. RESULTS: From 2010 to 2019, 17,283 patients underwent valve intervention. The MVS, SVAR, and TAVR accounted for the 39.4%, 48.2%, and 12.3% respectively of the whole. MetS compared to no-MetS was associated to higher mortality in the MVS group (6.5% vs. 2%, p < .001), but not in the SAVR and TAVR group. In both surgical cohorts, MetS was associated with increased complications including red blood cells transfusion, renal failure, mechanical ventilation time, intensive care and overall postoperative LOS (11 (9) vs. 10 (6), p < .001 and 10 (6) versus 10 (5) days, p = .002, MVS and [SAVR]). No differences were found in the TAVR cohort, with similar mortality and complications. CONCLUSION: MetS was associated to more postoperative complications, with higher mortality in the MVS group. In the TAVR cohort, postoperative complications and mortality rate did not differ between patients with and without MetS, however LOS was longer in the MetS group.
No takes yet. Share an insight, caveat, or question.
Moscarelli et al. (2022) conducted a cohort in Heart valve intervention (n=17,283). Metabolic syndrome vs. No metabolic syndrome was evaluated on In-hospital mortality and overall postoperative length of stay (p=<0.001). Metabolic syndrome was associated with higher in-hospital mortality following mitral valve surgery (6.5% vs. 2%, p<0.001), but not after surgical or transcatheter aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: